FectoVIR®-LV transfection reagent designed to improve Lentiviral vector (LV) titers in HEK-293 suspension cell systems.
Watch this webinar from Philippe Ledent, Chief Scientific Director at Xpress Biologics, now part of Sartorius and Rakel Lopez de Maturana, Qualified Person & Regulatory Affairs Director at VIVEbiotech discuss how to ensure gain of time and success of lentiviral-based therapies from process development up to market approval.
Key Learning Objectives:
- Meeting regulatory compliance for plasmids used for lentivirus manufacturing.
- Ensuring same manufacturing process and specifications for research to GMP grade plasmid manufacturing.
- Adaptable plasmid manufacturing platform is critical to accelerate lentivirus manufacturing